This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Tunisia, Turkey, UK.
The drug ALPHAGAN contains one active pharmaceutical ingredient (API):
1
|
UNII
4S9CL2DY2H - BRIMONIDINE TARTRATE
|
|
Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| ALPHAGAN P Ophthalmic solution / drops | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ALPHAGAN Eye drops, solution | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01EA05 | Brimonidine | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EA Sympathomimetics in glaucoma therapy |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 5298W, 5534G, 5563T, 8351M |
| BR | Câmara de Regulação do Mercado de Medicamentos | 501000301175318, 501000302171316, 501000401171314, 501006401171313, 501016060012403 |
| CA | Health Products and Food Branch | 02236876, 02248151 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 25.856-08-04 |
| EE | Ravimiamet | 1238880, 1609477, 1755806 |
| ES | Centro de información online de medicamentos de la AEMPS | 62010 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 174433, 174664 |
| FR | Base de données publique des médicaments | 68451230 |
| GB | Medicines & Healthcare Products Regulatory Agency | 138272, 13845, 140550, 161371, 374168 |
| HK | Department of Health Drug Office | 50368 |
| HR | Agencija za lijekove i medicinske proizvode | HR-H-063917030 |
| IE | Health Products Regulatory Authority | 11298, 11301, 11306, 13033 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 4785 |
| IT | Agenzia del Farmaco | 033490020, 044819011, 045282011, 045633017, 045769015 |
| MT | Medicines Authority | MA1304/00201 |
| MX | Comisión Federal para la Protección contra Riesgos Sanitarios | 147M98 |
| NL | Z-Index G-Standaard | 14181150 |
| NL | Z-Index G-Standaard, PRK | 50237 |
| NZ | Medicines and Medical Devices Safety Authority | 11926, 7798 |
| PL | Rejestru Produktów Leczniczych | 100100520 |
| SG | Health Sciences Authority | 09788P, 12336P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699490561041 |
| US | FDA, National Drug Code | 0023-9177, 0023-9321 |
| ZA | Health Products Regulatory Authority | A39/15.4/0202 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.